VT-1161 protects immunosuppressed mice from Rhizopus arrhizus var. arrhizus infection

Teclegiorgis Gebremariam, Nathan P. Wiederhold, Annette W. Fothergill, Edward P. Garvey, William J. Hoekstra, Robert J. Schotzinger, Thomas F. Patterson, Scott G. Filler, Ashraf S. Ibrahim

Research output: Contribution to journalArticlepeer-review

20 Scopus citations

Abstract

We studied the efficacy of the investigational drug VT-1161 against mucormycosis. VT-1161 had more potent in vitro activity against Rhizopus arrhizus var. arrhizus than against R. arrhizus var. delemar. VT-1161 treatment demonstrated dose-dependent plasma drug levels with prolonged survival time and lowered tissue fungal burden in immunosuppressed mice infected with R. arrhizus var. arrhizus and was as effective as high-dose liposomal amphotericin B treatment. These results support further development of VT-1161 against mucormycosis.

Original languageEnglish (US)
Pages (from-to)7815-7817
Number of pages3
JournalAntimicrobial agents and chemotherapy
Volume59
Issue number12
DOIs
StatePublished - Dec 1 2015

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'VT-1161 protects immunosuppressed mice from Rhizopus arrhizus var. arrhizus infection'. Together they form a unique fingerprint.

Cite this